LENZ THERAPEUTICS, INC. Net Income
LENZ THERAPEUTICS, INC. (LENZ) reported Net Income of -$31.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$31.92M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$41.49M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$35.90M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$16.70M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2025 was -$82.13M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2024 was -$49.77M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$69.97M.
- LENZ THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$101.05M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$31.92M 10-Q · filed 2026-08-11 | -$73.41M 10-Q · filed 2026-08-11 | -$109.30M derived: sum of 3 quarters · filed 2026-08-11 | -$126.00M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$41.49M 10-Q · filed 2026-08-11 | -$77.38M derived: sum of 2 quarters · filed 2026-08-11 | -$94.08M derived: sum of 3 quarters · filed 2026-08-11 | -$109.00M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$35.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$52.60M derived: sum of 2 quarters · filed 2026-03-24 | -$67.51M derived: sum of 3 quarters · filed 2026-08-11 | -$82.13M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | -$16.70M 10-Q · filed 2025-11-05 | -$31.61M derived: sum of 2 quarters · filed 2026-08-11 | -$46.23M 10-Q · filed 2025-11-05 | -$58.88M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$14.91M 10-Q · filed 2026-08-11 | -$29.53M 10-Q · filed 2026-08-11 | -$42.18M derived: sum of 3 quarters · filed 2026-08-11 | -$52.40M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$14.62M 10-Q · filed 2026-08-11 | -$27.27M derived: sum of 2 quarters · filed 2026-08-11 | -$37.49M derived: sum of 3 quarters · filed 2026-08-11 | -$47.74M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2024-12-31 | -$12.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$22.87M derived: sum of 2 quarters · filed 2026-03-24 | -$33.12M derived: sum of 3 quarters · filed 2026-03-24 | -$49.77M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$10.21M 10-Q · filed 2025-11-05 | -$20.47M derived: sum of 2 quarters · filed 2025-11-05 | -$37.12M 10-Q · filed 2025-11-05 | -$60.81M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$10.25M 10-Q · filed 2025-11-05 | -$26.90M 10-Q · filed 2025-07-30 | -$50.59M derived: sum of 3 quarters · filed 2025-11-05 | -$69.47M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | -$16.65M 10-Q · filed 2025-11-05 | -$40.34M derived: sum of 2 quarters · filed 2025-11-05 | -$59.22M derived: sum of 3 quarters · filed 2025-11-05 | -$73.95M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2023-12-31 | -$23.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$42.57M derived: sum of 2 quarters · filed 2025-03-19 | -$57.30M derived: sum of 3 quarters · filed 2025-03-19 | -$69.97M 10-K · filed 2025-03-19 | -$124.65M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$18.88M 10-Q · filed 2024-11-06 | -$22.48M 10-Q · filed 2023-11-13 | -$33.61M derived: sum of 2 quarters · filed 2024-11-06 | -$46.28M 10-Q · filed 2024-11-06 | -$101.73M 10-Q · filed 2023-11-13 | -$70.88M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | -$14.73M 10-Q · filed 2024-11-06 | -$55.31M 10-Q · filed 2023-08-14 | -$27.40M 10-Q · filed 2024-08-14 | -$79.25M 10-Q · filed 2023-08-14 | -$51.99M derived: sum of 3 quarters · filed 2024-11-06 | -$76.68M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-03-31 | -$12.67M 10-Q · filed 2024-11-06 | -$23.93M 10-Q · filed 2023-05-11 | -$37.27M derived: sum of 2 quarters · filed 2024-11-06 | -$61.95M derived: sum of 3 quarters · filed 2024-11-06 | -$87.89M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2022-12-31 | -$24.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$49.28M derived: sum of 2 quarters · filed 2024-02-27 | -$75.22M derived: sum of 3 quarters · filed 2024-02-27 | -$101.05M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | -$24.68M 10-Q · filed 2023-11-13 | -$50.62M derived: sum of 2 quarters · filed 2023-11-13 | -$76.45M 10-Q · filed 2023-11-13 | -$95.38M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$25.94M 10-Q · filed 2023-11-13 | -$51.77M 10-Q · filed 2023-08-14 | -$70.70M derived: sum of 3 quarters · filed 2023-11-13 | -$85.29M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-03-31 | -$25.84M 10-Q · filed 2023-11-13 | -$44.77M derived: sum of 2 quarters · filed 2023-11-13 | -$59.36M derived: sum of 3 quarters · filed 2023-11-13 | -$76.89M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2021-12-31 | -$18.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$33.52M derived: sum of 2 quarters · filed 2023-03-20 | -$51.05M derived: sum of 3 quarters · filed 2023-03-20 | -$70.76M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$14.59M 10-Q · filed 2022-11-09 | -$32.12M derived: sum of 2 quarters · filed 2022-11-09 | -$51.83M 10-Q · filed 2022-11-09 | -$115.37M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$17.53M 10-Q · filed 2022-08-11 | -$37.24M 10-Q · filed 2022-08-11 | -$100.77M derived: sum of 3 quarters · filed 2022-11-09 | -$104.16M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-03-31 | -$19.71M 10-Q · filed 2022-11-09 | -$83.25M derived: sum of 2 quarters · filed 2022-11-09 | -$86.63M derived: sum of 3 quarters · filed 2022-11-09 | -$87.94M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2020-12-31 | -$63.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$66.92M derived: sum of 2 quarters · filed 2022-03-21 | -$68.23M derived: sum of 3 quarters · filed 2022-03-21 | -$68.37M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | -$3.38M 10-Q · filed 2021-11-10 | -$4.70M derived: sum of 2 quarters · filed 2021-11-10 | -$4.84M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$1.31M 10-Q · filed 2021-08-12 | -$1.45M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |